* If you want to update the article please login/register
Background: Methotrexate is the first line treatment of rheumatoid arthritis, and methylation changes in bulk T cells have been reported following MTX therapy. Before and after the MTX treatment of RA patients, we've investigated cell-type specific DNA methylation changes in nave and memory CD4+ T cells. Reduced representation bisulfite sequencing of newly diagnosed RA patients were compared by reduced representation bisulfite sequencing. Results: We discovered that MTX treatment had a significant effect on DNA methylation levels at several CpG sites in both cell populations. Conclusion: In CD4+ na've and memory T cells isolated from RA patients, we found CpG sites that were linked to MTX therapy. Overall scheme: We've investigated cell-type specific DNA methylation changes in na've and memory CD4+ T cells before and after MTX therapy of RA patients. Reduced representation bisulfite sequencing was used to determine methylation profiles of newly diagnosed RA patients.
Source link: https://www.ncbi.nlm.nih.gov/bioproject/779093
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions